Stockhead: The quiet catalyst: Why open-label extension trials matter for ASX biotechs
While main trial results tend to attract the big headlines for biotech companies, lower-profile open-label extension (OLE) trials can tell an equally important story.
Morgans senior healthcare analyst Scott Power told Stockhead that in an OLE, patients who complete the main trial can keep taking the drug, and everyone knows what they are receiving, with no placebo or no blinding.
“Open-label extension studies provide long-term follow-up after the main trial, giving all participants access to the active treatment,” he said.
“Their primary value lies in demonstrating safety and persistence of benefit over time, rather than generating definitive efficacy data.
“Positive extension results can strengthen the overall evidence package and increase confidence among regulators, clinicians and investors.”
Read more, including an overview of the Actinogen OLE by clicking the following link:
This article also appeared in The Australian and across all major News Corp mastheads on 21 October 2026